The American journal of gastroenterology
-
Am. J. Gastroenterol. · Feb 2006
Randomized Controlled Trial Multicenter StudyThe gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
While traditional nonsteroidal antiinflammatory drugs (t-NSAIDs) are relatively contraindicated in patients with inflammatory bowel disease (IBD) for fear of disease aggravation, controlled clinical trials showed that cyclo-oxygenase-2 inhibitors have fewer gastrointestinal side effects than the t-NSAIDs. Etoricoxib is a new antiinflammatory inhibitor that has high Cox-2 selectivity. ⋯ Etoricoxib therapy is safe and beneficial in most patients with IBD treatment with etoricoxib was not associated with exacerbation of the underlying IBD- and GI-related complications.
-
Am. J. Gastroenterol. · Feb 2006
ReviewDoes fecal occult blood testing really reduce mortality? A reanalysis of systematic review data.
Colorectal cancer (CRC) is a common cause of cancer mortality. A variety of CRC screening strategies are being adopted in many developed countries. Fecal occult blood testing (FOBT) is one option for screening that has the most evidence for efficacy and is also the cheapest approach. Systematic reviews suggest that FOBT is effective in reducing CRC mortality but the data on overall mortality from any cause has rarely been synthesized. ⋯ The impact of FOBT in reducing mortality from any cause is uncertain and efficacy of this strategy for CRC screening needs reevaluation.
-
Am. J. Gastroenterol. · Jan 2006
Randomized Controlled Trial Multicenter Study Comparative StudyRisk factors for post-ERCP pancreatitis: a prospective multicenter study.
Pancreatitis is the most common and serious complication of diagnostic and therapeutic ERCP. The aim of this study is to examine the potential patient- and procedure-related risk factors for post-ERCP pancreatitis in a prospective multicenter study. ⋯ This study emphasizes the role of patient factors (age, SOD, prior history of post-ERCP pancreatitis) and technical factors (number of PD injections, minor papilla sphincterotomy, and operator experience) as the determining high-risk predictors for post-ERCP pancreatitis.
-
Am. J. Gastroenterol. · Dec 2005
Randomized Controlled Trial Comparative StudyPremedication with intravenous ketorolac trometamol (Toradol) in colonoscopy: a randomized controlled trial.
We conducted a prospective double-blinded placebo-controlled randomized trial to investigate the effect of ketorolac trometamol (KT) administered intravenously as premedication in colonoscopy. ⋯ Premedication with IV KT (Toradol) improves pain control during colonoscopy with no associated serious complications.
-
Am. J. Gastroenterol. · Dec 2005
Deep sedation occurs frequently during elective endoscopy with meperidine and midazolam.
Although moderate (conscious) sedation is intended during elective gastrointestinal endoscopy, unintended levels of deep sedation occur. The aims of this study were to prospectively evaluate the incidence and risk factors of deep sedation during elective endoscopy with meperidine and midazolam intended to maintain a level of moderate sedation. ⋯ Deep sedation occurs frequently during elective endoscopy with meperidine and midazolam used with the intent of moderate sedation. ERCP and EUS are risk factors for the occurrence of deep sedation, independent of sedation dose or length of procedure.